BINVBioInvent International ABBINV info
$4.02info1.86%24h
Global rank15512
Market cap$264.29M
Change 7d-
YTD Performance118.09%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    BioInvent International AB (BINV) Stock Overview

    BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

    BINV Stock Information

    Symbol
    BINV
    Address
    The Gamma BuildingLund, 223 70Sweden
    Founded
    -
    Trading hours
    -
    Website
    https://www.bioinvent.com
    Country
    πŸ‡ΈπŸ‡ͺ Sweden
    Phone Number
    46 4 62 86 85 50

    BioInvent International AB (BINV) Price Chart

    -
    Value:-

    BioInvent International AB Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $4.02
    N/A
    Market Cap
    $264.29M
    N/A
    Shares Outstanding
    65.80M
    N/A
    Employees
    108.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org